WXIBF (WuXi Biologics (Cayman)) Moat Score: 7/10 (As of Jul. 01, 2026)


WXIBF WuXi Biologics (Cayman) Inc WXIBF
97 GF Score
Price $4.00
GF Value $5.11
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Moat Score?

WuXi Biologics (Cayman) WXIBF -9.09% 97 Moat Score is 7 as of Jul. 01, 2026. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $5.11 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 99.57% on this metric.

WuXi Biologics (Cayman) has the Moat Score of 7, which implies that the company might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

WuXi Biologics (Cayman) has Wide Moat: WuXi Biologics possesses a wide moat due to its strong R&D capabilities, valuable intellectual property, and significant regulatory barriers. It has a robust market position in biologics manufacturing, supported by economies of scale and a superior distribution network.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes WuXi Biologics (Cayman) might have Wide Moat - Entry-level wide moat, clearly possessing durable advantages.

WuXi Biologics (Cayman)  (OTCPK:WXIBF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

WuXi Biologics (Cayman) Moat Score Related Terms

WXIBF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman) Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Moat Score distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Moat Score falls into.


WXIBF
97GF Score
WuXi Biologics (Cayman) Inc WXIBF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 7 mean?
WuXi Biologics (Cayman) (WXIBF) has a Moat Score of 7 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #6 out of 1400 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is WuXi Biologics (Cayman)'s Moat Score too high?
WuXi Biologics (Cayman)'s current Moat Score is 7. The Biotechnology industry median Moat Score is 2.00. WuXi Biologics (Cayman)'s value of 7 is 250% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #6 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #6 out of 1400 companies for Moat Score. This places WuXi Biologics (Cayman) in the top 0% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. WuXi Biologics (Cayman)'s value of 7 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Moat Score of 7 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Moat Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.11, compared to a current price of $4.00 — trading 21.7% below its estimated fair value. The current Moat Score is 7 and 250% above the Biotechnology industry median of 2.00. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Moat Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of $4.00 is trading 21.7% below its estimated GF Value™ of $5.11. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for WXIBF:

  • Moat Score: 7
  • GF Value™: $5.11 vs. price of $4.00 (21.7% below fair value)
  • GF Score™: 97/100 with 3 warning signs
  • Industry Position: 250% above the Biotechnology median (#6 of 1400)

No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score

Get the complete analysis for WXIBF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$5.11
GF Value